Canaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $136.00

Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) had its price objective boosted by Canaccord Genuity Group from $121.00 to $136.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company's stock.

A number of other research analysts have also recently commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 22nd. TD Cowen upped their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, October 21st. JPMorgan Chase & Co. lowered their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, November 21st. Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday, December 20th. Finally, Piper Sandler upped their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $93.50.

Ultragenyx Pharmaceutical Stock Down 4.2 %

Shares of RARE stock traded down $1.89 on Tuesday, reaching $42.59. The company had a trading volume of 616,022 shares, compared to its average volume of 881,342. The stock has a market capitalization of $3.93 billion, a PE ratio of -6.72 and a beta of 0.60. Ultragenyx Pharmaceutical has a one year low of $37.02 and a one year high of $60.37. The business's 50-day moving average is $43.15 and its 200 day moving average is $49.42.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 185.70% and a negative net margin of 101.60%. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 11,727 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now owns 2,183,985 shares of the company's stock, valued at $92,229,686.55. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.80% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds have recently modified their holdings of the stock. Van ECK Associates Corp increased its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock valued at $928,000 after acquiring an additional 294 shares in the last quarter. Motley Fool Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the 3rd quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company's stock valued at $8,005,000 after acquiring an additional 360 shares in the last quarter. BOKF NA increased its stake in shares of Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after acquiring an additional 382 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.